Show simple item record

Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma

dc.contributor.authorKobak, Senol
dc.date.accessioned2021-03-03T21:04:05Z
dc.date.available2021-03-03T21:04:05Z
dc.date.issued2019
dc.identifier.citationKobak S., "Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma", CURRENT DRUG SAFETY, cilt.14, sa.3, ss.225-229, 2019
dc.identifier.otherav_5d34293f-2e97-4682-9db1-09334d74841b
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/65277
dc.identifier.urihttps://doi.org/10.2174/1574886314666190528121039
dc.description.abstractBackground: Immune checkpoint inhibitors (CPIs) are new promising anti-cancer drugs that block negative costimulation of T-cells leading to an enhanced anti-tumor immune response. Pembrolizumab, an a monoclonal antibody, targeting the programmed cell death protein 1 (PD-1) pathway. CPIs have been associated with a number of immune-related adverse events (AEs), including musculoskeletal and rheumatic disease.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titlePembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
dc.typeMakale
dc.relation.journalCURRENT DRUG SAFETY
dc.contributor.departmentAnkara Liv Hospital , ,
dc.identifier.volume14
dc.identifier.issue3
dc.identifier.startpage225
dc.identifier.endpage229
dc.contributor.firstauthorID260042


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record